ETHACRYNIC ACID TABLETS
MARKETED BY
: Lupin Limited
COMPARE TO: Edecrin
Following an earlier FDA approval, Lupin Limited is launching generic ethacrynic acid tablets for the treatment of edema when an agent with greater diuretic potential than commonly prescribed drugs is required. Possible uses include treatment of patients who have edema associated with cirrhosis of the liver, congestive heart failure, or renal disease; short-term management of ascites because of idiopathic edema, lymphedema, or malignancy; and short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease. The tablets are available in 25-mg doses.
FOR MORE INFORMATION: lupinpharmaceuticals.com




ALBUTEROL SULFATE INHALATION AEROSOL
MARKETED BY
: Perrigo Company plc
COMPARE TO: ProAir HFA
Albuterol inhalation aerosol can be used to prevent or treat bronchospasm in patients with asthma or certain types of chronic obstructive pulmonary disease. It is approved for use in adults and children 4 years and older. This FDA approval marks the first AB-rated generic version of ProAir HFA. Gross sales of ProAir HFA were about $1.4 billion over the previous 12 months, according to a statement from Perrigo. Common adverse effects include chest pain, increased thirst, and wheezing.
FOR MORE INFORMATION: perrigo.com




FLUVOXAMINE MALEATE TABLETS
MARKETED BY
: Upsher-Smith
COMPARE TO: Luvox
Upsher-Smith has launched its generic fluvoxamine maleate tablets, approved to treat patients with obsessive-compulsive disorder. The drug is available in 25-, 50-, and 100-mg strengths and had a market value of about $28 million for the 12 months ending September 2019. The product comes with a boxed warning for suicidal behaviors and thoughts for children, adolescents, and young adults who take antidepressants.
FOR MORE INFORMATION: upsher-smith.com




NAPROXEN AND ESOMEPRAZOLE MAGNESIUM DELAYEDRELEASE TABLETS
MARKETED BY
: Dr. Reddy’s
COMPARE TO: Vimovo
Dr. Reddy’s is launching its first-tomarket naproxen and esomeprazole magnesium delayed-release tablets, a nonsteroidal anti-inflammatory drug that reduces substances in the body that cause fever, inflammation, and pain. It is approved for patients 12 years and older who weigh at least 84 pounds, including adults with ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis, as well as children with juvenile idiopathic arthritis. Adverse effects can include chest pain, difficulty breathing, nausea, and upper stomach pain. The tablets are available in 375-mg/20-mg and 500-mg/20-mg doses in 60-count bottles.
FOR MORE INFORMATION: drreddys.com